The global amyotrophic lateral sclerosis treatment market size was valued at USD 746.7 million in 2025 and is projected to grow from USD 790.0 million in 2026 to USD 1.17 billion in 2033, at a CAGR of 5.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.5% in 2025. The increasing incidence and prevalence of amyotrophic lateral sclerosis (ALS), particularly sporadic ALS, which affects a large number of patients, is a major driver of market growth.
Furthermore, the growing geriatric population, a key risk factor for ALS, is also contributing to the rise in cases. As the population ages, the demand for effective treatment options is likely to increase.
The growing focus on developing targeted therapies and disease-modifying treatments is expected to drive innovation in the ALS treatment landscape. For instance, in December 2025, Biogen announced that long-term results from the Phase 3 VALOR study and its open-label extension demonstrated that early treatment with QALSODY (tofersen) was associated with a slower decline in clinical function, breathing, and muscle strength in patients with SOD1-associated ALS. The findings highlight the increasing progress in precision medicine and gene-targeted therapies aimed at improving outcomes for ALS patients.
Increased awareness and diagnosis are also key drivers of market growth. Rising awareness among patients and healthcare professionals about ALS and available treatment options is boosting diagnosis rates and driving demand for ALS drugs. This increased awareness is likely to lead to earlier diagnosis and treatment, resulting in better patient outcomes and increased market growth.
Favorable reimbursement policies and expansion of distribution channels are also supporting market growth. In regions such as North America, favorable reimbursement policies for ALS treatments are facilitating access to these therapies and driving market growth. The increasing availability of ALS drugs through hospital pharmacies, retail pharmacies, and online channels is broadening patient access and boosting market growth. As the market continues to evolve, these factors are likely to drive further growth and expansion.
▪ Edaravone
▪ Others
▪ Canada
▪ Mexico
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ Denmark
▪ Sweden
▪ Norway
▪ China
▪ India
▪ Australia
▪ South Korea
▪ Thailand
▪ Argentina
▪ Saudi Arabia
▪ UAE
▪ Kuwait
Furthermore, the growing geriatric population, a key risk factor for ALS, is also contributing to the rise in cases. As the population ages, the demand for effective treatment options is likely to increase.
The growing focus on developing targeted therapies and disease-modifying treatments is expected to drive innovation in the ALS treatment landscape. For instance, in December 2025, Biogen announced that long-term results from the Phase 3 VALOR study and its open-label extension demonstrated that early treatment with QALSODY (tofersen) was associated with a slower decline in clinical function, breathing, and muscle strength in patients with SOD1-associated ALS. The findings highlight the increasing progress in precision medicine and gene-targeted therapies aimed at improving outcomes for ALS patients.
Increased awareness and diagnosis are also key drivers of market growth. Rising awareness among patients and healthcare professionals about ALS and available treatment options is boosting diagnosis rates and driving demand for ALS drugs. This increased awareness is likely to lead to earlier diagnosis and treatment, resulting in better patient outcomes and increased market growth.
Favorable reimbursement policies and expansion of distribution channels are also supporting market growth. In regions such as North America, favorable reimbursement policies for ALS treatments are facilitating access to these therapies and driving market growth. The increasing availability of ALS drugs through hospital pharmacies, retail pharmacies, and online channels is broadening patient access and boosting market growth. As the market continues to evolve, these factors are likely to drive further growth and expansion.
Amyotrophic Lateral Sclerosis Treatment Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global amyotrophic lateral sclerosis treatment market report by treatment, type, distribution channel, and region:Treatment Outlook (Revenue, USD Million, 2021 - 2033)
- Medication
▪ Edaravone
▪ Others
- Stem Cell Therapy
- Others
Type Outlook (Revenue, USD Million, 2021 - 2033)
- Sporadic ALS
- Familial ALS
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
▪ Canada
▪ Mexico
- Europe
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ Denmark
▪ Sweden
▪ Norway
- Asia Pacific
▪ China
▪ India
▪ Australia
▪ South Korea
▪ Thailand
- Latin America
▪ Argentina
- Middle East & Africa
▪ Saudi Arabia
▪ UAE
▪ Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Amyotrophic Lateral Sclerosis Treatment Market Variables, Trends, & Scope
Chapter 4. Amyotrophic Lateral Sclerosis Treatment Market: Treatment Estimates & Trend Analysis
Chapter 5. Amyotrophic Lateral Sclerosis Treatment Market: Type Estimates & Trend Analysis
Chapter 6. Amyotrophic Lateral Sclerosis Treatment Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. Amyotrophic Lateral Sclerosis Treatment Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
- Tanabe Pharma Corporation
- Biogen
- BrainStorm Cell Limited
- Amylyx Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Sanofi
- Otsuka Pharmaceutical Co. Ltd.
- F. Hoffmann-La Roche Ltd
- AB Science
- Sun Pharmaceutical Industries Ltd.
- Orion Corporation
- CORESTEMCHEMON Inc.
